Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...

Reviewed by Julia M. Cunningham, MD, Assistant Professor, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Patients with immune thrombocytopenia (ITP) ...

Formerly known as idiopathic thrombocytopenic purpura, immune thrombocytopenia (ITP) is an acquired autoimmune condition characterized by increased platelet destruction and impaired platelet ...

What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, ...

Sanofi’s Wayrilz, the first BTK inhibitor to treat immune thrombocytopenia gets European approval: Paris Saturday, December 27, 2025, 12:00 Hrs [IST] Sanofi, an R&D driven, AI-p ...

ITP affects about 5 people per 10,000. It can be associated with other conditions that are hematologic (leukemia) or ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Over two dozen cases of the rare blood disorder thrombocytopenia have been reported in people who have received COVID vaccines in the U.S. However, a link between COVID vaccines and the disease that ...

What can you tell me about the cause and treatment of immune thrombocytopenia purpura (ITP)? I am a 71-year-old male, and ...